Study Findings on Novel Agents in Neoplastic Hematology

The last of four studies featured in this article details results from a single-center phase I trial with idasanutlin, an MDM2 inhibitor, in patients with high-risk polycythemia vera and essential thrombocythemia without prior JAK2 inhibitor therapy. The study shows tolerability and improvement in total symptom score. Multicenter phase II trials in patients with hydroxyurea-resistant disease are underway.

 The ASCO Post

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.